A Randomized Parallel Comparison of Semaglutide versus Placebo on Intestinal Barrier (SIB)

Primary Objective

Investigate the effects of short-term treatment (16 weeks) of semaglutide as compared to placebo on intestinal permeability in subjects with T2D.

Is this Study for You?

Let's Get Started!


Participants should be type 2 diabetic and be treated with metformin only. Each participant will complete 7-8 visits. After screening, participants will be given either semaglutide or a placebo and will be asked to self-administer the medication once weekly. Study visits will include blood draws and frequent urine samples. Participants will also be asked to provide a stool sample after screening and at their final in-person visit.

Main Procedures Involved: Blood draw, lactulose mannitol ratio test (urine test), vitals, stool samples, subcutaneous injection of semaglutide or placebo once weekly.

Duration of Participation: 5-6 months


18 to 79 years


compensation provided


CU Anschutz non-hospital research facilities

Study ID

Protocol Number: 21-2774

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers